Curia published an article titled A few takeaways from my latest article on the transition from selling to executing in a CDMO partnership.
Public source
Publisher name
Public post
A sponsor shouldn’t have to reintroduce their program every time someone new joins the conversation. Yet it happens more often than we probably realize. A few takeaways…
Company
Curia
From curiosity to cure
- Industry
- Pharmaceutical Manufacturing
- Location
- Albany, US
- Company size
- 1,001–5,000 employees
About Curia
Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 25 global sites and 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.
See moreLatest activity
Latest activity from Curia
10 signals
Partnerships
Curia was selected by eXoZymes as its commercial-scale manufacturing partner for NCT, with teams in León, Spain, and Rozzano, Italy scaling the proprietary NCT process.
Products & Services
Curia published a new resource breaking down how the company helps customers navigate the specific requirements of the MHLW and PMDA, from J-DMF registration through commercial supply.
Presence & Recognition
Curia's Drug Product team will be present at Contract Pharma in New Jersey from September 24 to 25 to highlight parenteral Formulation Development expertise and Clinical/Commercial Fill Finish sites.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Afton Scientific, LLC
Afton Scientific, LLC published an article examining how CDMOs help sponsors navigate supply chain control, traceability, and regulatory compliance from sourcing through delivery.
Research & Knowledge
53Biologics
53Biologics published an article exploring questions that help distinguish a capable service provider from a CDMO prepared to take ownership and keep the program moving when the stakes increase.
Research & Knowledge
Alcura
Alcura published an article exploring the operational coordination and sourcing complexity shaping modern global clinical trials.
Research & Knowledge
CARBOGEN AMCIS
CARBOGEN AMCIS published How to Successfully Move from Clinical to Commercial Manufacturing.
Research & Knowledge
Uniphar | Clinical